Q2 2026 saw 4% sales growth, with Medical Solutions leading and strong cash flow supporting acquisitions. Margins were pressured by raw material costs, but most impacts are expected to normalize after Q3. Medical and Engineered Solutions segments both contributed to growth.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.